Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,051.25 +36.04 (+3.55%)
Streaming Delayed Price Updated: 3:00 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
News headline image
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs ↗
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes. 
Via Benzinga
News headline image
Eli Lilly Stock: Elevated Momentum, Strong Analyst Backing, Near-Term Earnings Focus ↗
Eli Lilly's stock shows robust momentum and strong analyst support, driven by solid fundamentals and positive market sentiment, while upcoming earnings releases remain a focal point for investors. 
Via Talk Markets
Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials ↗
Via Stocktwits
News headline image
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026 ↗
The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value. 
Via The Motley Fool
News headline image
New to Investing? These Are 3 Solid Blue Chip Stocks You Can Build Your Portfolio Around ↗
Regardless of your investing knowledge or experience, you can't go wrong with these three behemoths in your portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Smart Money Is Betting Big In LLY Options ↗
 
Via Benzinga
News headline image
1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today ↗
Despite the company's run in recent years, it's not too late to buy. 
Via The Motley Fool
News headline image
Independence Bank of Kentucky Buys Another $3.1 Million Eli Lilly (NYSE: LLY) Shares ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
3 Healthcare Companies Insiders Are Buying ↗
Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years. 
Via MarketBeat
Topics Initial Public Offering
News headline image
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly ↗
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
Via Stocktwits
News headline image
Jim Cramer Declares Wall Street Divided: Three Distinct Markets Emerge
Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Recent Filing Shows That Sen. John Boozman Bought Over $49K Worth of iShares 7-10 Year Treasury Bond ETF Stock ↗
 
Via Benzinga
Topics ETFs
News headline image
Down 44%, Should You Buy the Dip on Viking Therapeutics? ↗
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
News headline image
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs ↗
 
Via Benzinga
News headline image
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street ↗
Is it too late to get on the bandwagon? 
Via The Motley Fool
News headline image
The Smartest Growth Stock to Buy With $100 Right Now ↗
This beaten-down drugmaker is well positioned to turn things around. 
Via The Motley Fool
News headline image
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗
Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
Via The Motley Fool
Topics ETFs Government World Trade
News headline image
Should You Buy Novo Nordisk Right Now? ↗
The fallen pharma giant could make a big comeback in 2026. 
Via The Motley Fool
News headline image
Should Investors Buy Eli Lilly Stock? ↗
Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies. 
Via The Motley Fool
News headline image
MarketBeat Week in Review – 10/06 - 10/10 ↗
Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data 
Via MarketBeat
Topics Economy
News headline image
Why Hims & Hers Health (HIMS) Stock Is Nosediving
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue... 
Via StockStory
Topics World Trade
News headline image
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations ↗
Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries. 
Via Benzinga
News headline image
1 Vanguard ETF to Invest In That Can Turn $500 Monthly Into $800,000 ↗
This ETF has shown market-beating potential since its inception. 
Via The Motley Fool
Topics ETFs
News headline image
2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now ↗
Ongoing developments make these companies look attractive. 
Via The Motley Fool
Topics Economy World Trade
News headline image
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions
Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in... 
Via MarketMinute
News headline image
Direxion's QQQU, QQQD ETFs Foster A Diversified Approach To Magnificent 7 Speculation ↗
 
Via Benzinga
Topics ETFs
News headline image
5 Healthcare Plays Powering the Sector’s Big Comeback ↗
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest. 
Via MarketBeat
News headline image
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market ↗
Roche has a promising GLP-1 drug that is entering phase 3 trials. 
Via The Motley Fool
News headline image
Amazon's Dual Thrust: Prime Discounts and Pharmacy Expansion Reshape Retail and Healthcare Landscapes
Amazon (NASDAQ: AMZN) continues to aggressively expand its strategic business developments, solidifying its e-commerce dominance through frequent Prime discount events and making significant inroads... 
Via MarketMinute
Topics Artificial Intelligence Economy
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.